Long-Term Growth and Monitoring Your Child's Health
At a Glance
Children with congenital enteropeptidase deficiency can often achieve catch-up growth when pancreatic enzyme replacement therapy is taken consistently. Lifelong follow-up tracks growth, blood proteins, anemia, vitamins, minerals, and clotting to guide care.
The most important message for families after a diagnosis of congenital enteropeptidase deficiency is one of hope. While the road to finding an answer was likely difficult, treatment with Pancreatic Enzyme Replacement Therapy (PERT) has shown excellent results in published cases. With consistent daily care, the long-term outlook for reported children has been very encouraging, allowing them to overcome their early struggles and grow [1][2].
A Positive Long-Term Outlook
Because this condition is so rare, there are very few documented cases following children into adulthood, meaning long-term outcomes across a lifespan are still incompletely defined. However, the evidence from reported pediatric cases is highly positive [1].
- Physical Development: Once the treatment begins and the body can digest nutrients, children typically enter a period of “catch-up growth.” Research has shown that physical development can normalize effectively with sustained treatment [1].
- Resolution of Complications: Severe issues seen at diagnosis—such as anemia, low blood protein, and skin rashes—generally resolve and do not return as long as treatment is maintained [1][2]. If symptoms do return, it is a sign that prompt specialist review is needed.
Your Individualized Monitoring Plan
Regular “surveillance” (scheduled checkups and labs) is necessary to ensure your child’s treatment is keeping up with their growing body. Because every child is different, your treating team will individualize your test schedule [1][3]. Your team may monitor:
| Category | What is Monitored | Why it Matters |
|---|---|---|
| Growth Metrics | Height, weight, and head circumference [1]. | Ensures your child is maintaining a healthy “growth velocity” (the rate of growth over time). |
| Blood Proteins | Serum Albumin and Total Protein [1][3]. | These markers help confirm the body is maintaining enough protein to prevent swelling (edema), though they can also be affected by inflammation or liver function. |
| Anemia Check | Complete Blood Count (CBC) and Iron levels [1][3]. | Monitors for the return of anemia or iron deficiency. |
| Micronutrients | Fat-soluble vitamins (A, D, E, K), Zinc, and Calcium [4][5]. | Checked according to your child’s clinical course and nutritional risk. |
| Coagulation | PT/INR tests [1]. | Checks that the blood is clotting correctly, which reflects vitamin K status and liver function. |
Daily Management: The “New Normal”
Managing this condition is a marathon, not a sprint. Because the body lacks the “starter” enzyme permanently, treatment is lifelong.
The core of daily management is the consistent administration of PERT exactly as prescribed by your doctor.
- Follow the Prescription: Do not guess the dose based on how much protein your child eats. Standard pancreatic enzyme products are prescribed using product-specific enzyme units and specific meal/snack dosing rules. Follow your specialist’s exact instructions [1].
- Consistency is Key: Skipping doses can lead to the return of loose stools, gas, or poor weight gain over time.
- Adjusting for Growth: As your child grows and begins eating solid foods, their nutritional and medication needs will change. You will work closely with your pediatric gastroenterologist and dietitian to adjust the plan safely [1].
By staying diligent with daily enzymes and regular checkups, you are providing your child with the foundation they need for a healthy, active life [1][2].
Common questions in this guide
Can children with congenital enteropeptidase deficiency catch up in growth?
What tests are used to monitor my child's health?
Does my child need enzyme replacement therapy for life?
What signs should prompt a call to my child's specialist?
How will enzyme treatment change as my child grows?
Get notified when new evidence is published on Congenital enteropathy due to enteropeptidase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (5)
- 1
Enterokinase deficiency associated with novel TMPRSS15 gene mutations: a case report.
Li Y, Li R, Pan Y, et al.
Frontiers in pediatrics 2025; (13()):1484208 doi:10.3389/fped.2025.1484208.
PMID: 39944319 - 2
Enterokinase deficiency with novel TMPRSS15 gene mutation masquerading as acrodermatitis enteropathica.
Chen Y, Li Z, Liu C, Wang S
Pediatric dermatology 2023; (40(2)):389-391 doi:10.1111/pde.15197.
PMID: 36410965 - 3
Activation of Human Pancreatic Proteolytic Enzymes: The Role of Enteropeptidase and Trypsin.
Freiburghaus AU, Roduner J, Hadorn HB
JPGN reports 2021; (2(4)):e138 doi:10.1097/PG9.0000000000000138.
PMID: 37206452 - 4
Secondary Hyperparathyroidism in Primary Intestinal Lymphangiectasia: A Report of Four Cases.
Zhang DX, Hao K, Zhang L, et al.
Gastroenterology research 2025; (18(3)):152-158 doi:10.14740/gr2022.
PMID: 40503188 - 5
Efficacy and safety of parenteral vitamin D therapy in infants and children with vitamin D deficiency caused by intestinal malabsorption.
Yu SB, Lee Y, Oh A, et al.
Annals of pediatric endocrinology & metabolism 2020; (25(2)):112-117 doi:10.6065/apem.1938142.071.
PMID: 32615691
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric gastroenterologist and dietitian should interpret growth and laboratory results and adjust enzyme treatment.